Incidence of Haemophilus influenzae Type b Disease in The Gambia 14 Years after Introduction of Routine Haemophilus influenzae Type b Conjugate Vaccine Immunization - 16/06/13
Abstract |
Objective |
Haemophilus influenzae type b (Hib) conjugate vaccine was first introduced in Africa in The Gambia in 1997 as a primary 3-dose course in infancy with no booster, and was followed by the disappearance of invasive Hib disease by 2002. A cluster of cases detected non-systematically in post-infant children in 2005-2006 raised the question of the need for a booster dose. The objective of this study was to determine the incidence of invasive Hib disease in Gambian children 14 years after the introduction of Hib conjugate vaccine.
Study design |
This hospital-based clinical and microbiological Hib disease surveillance in 3 hospitals in the western region of The Gambia was undertaken between October 2007 and December 2010 applying the same methods used in a previous Hib vaccine effectiveness study in 1997-2002.
Results |
The annual incidences of Hib meningitis and all invasive Hib disease in children aged <5 years remained below 5 cases per 100 000 children during 2008-2010. The median age of patients with any invasive Hib disease was 5 months.
Conclusion |
Hib conjugate vaccination as a primary 3-dose course in The Gambia remains highly effective in controlling invasive Hib disease, and current data do not support the introduction of a booster dose.
Le texte complet de cet article est disponible en PDF.Keyword : Hib
Plan
Funded by the GAVI Hib Initiative and Medical Research Council UK. |
|
Please see the Author Disclosures at the end of this article. |
Vol 163 - N° 1S
P. S4-S7 - juillet 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?